Recursion Pharmaceuticals (RXRX) Stock Price

Financial Performance

Recursion Pharmaceuticals reported an impressive revenue growth of 226.9% from the previous quarter and a modest year-over-year increase of 2.3%. However, gross profit was negative at -$7.1M, indicating that cost of goods sold exceeded revenues. The operating income also decreased by -4.1% from the previous quarter and -90.3% year over year which is concerning for investors as it indicates decreasing operational efficiency and profitability.

The company's EBITDA ratio stood at -12.98, further confirming its unprofitability in the recent period. The PE ratio is also negative (-2.55), suggesting that the company is not generating profits currently.

Stock Price

The stock price has been on a downward trend with a decrease of -20.1% in the last month and -22.1% YoY, trading currently at $4.61 which is significantly lower than its 200-day moving average ($6.04). This suggests bearish market sentiment towards Recursion Pharmaceuticals' stock.

The RSI value stands at 32.33 indicating that the stock might be nearing oversold territory where it could potentially bounce back if other factors align positively.

Alternative Data Signals

In terms of alternative data signals, website traffic trends are positive with an increase of 4.9% month over month and a substantial increase of 50.9% YoY indicating growing interest in Recursion Pharmaceuticals' activities or products.

The number of job openings has increased by 28.6% MoM and by 35% YoY which could indicate expansion plans or high turnover rates within the company – both situations requiring careful consideration by potential investors.

The company's social media presence has shown significant growth in the last 90 days with Twitter followers increasing by 81.6% and Facebook followers by 45.5%. This could indicate growing public interest or effective social media marketing strategies.

Conclusion

In conclusion, while Recursion Pharmaceuticals' revenue trends and web traffic are positive, its financial performance is concerning with negative gross profit and operating income. The declining stock price also suggests bearish investor sentiment. Therefore, the analysis for Recursion Pharmaceuticals' stock is neutral to slightly bearish.

Note: This AI Stock Analysis is based on data as of September 06. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $4.62, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.